Est. 2001·3,000+ placements · six offices · four regions
M&A Activitycurated sourcedetected 2026-08-06 · confidence 70%

Last updated

Teva Pharmaceuticals: M&A Activity

Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices

Source: Endpoints News

Who
Teva Pharmaceuticals · Biotech & Pharma · USA
What happened
Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices
When
2026-08-06

Market context: This lands while the Talent Market Index reads 95.4 (Cool) — down 5.3 versus the prior month — and Americas signal share is easing (-16.2pts).

Teva Pharmaceuticals: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Oceania signal flow; 4 tracked across 50 days.

MitchelLake in this thematic

Also at Teva Pharmaceuticals →

More signals across Biotech & Pharma

M&A Activity · Americas

Repligen Corporation →

Repligen completed acquisition of BioLife Solutions for $11.25/share cash plus stock consideration. Transaction consolidates cell therapy bioprocessing capabilities and expands Repligen's product portfolio in high-growth cell and gene therapy market.

M&A Activity · Americas

Amgen →

Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.

M&A Activity · Americas

BioMarin Pharmaceutical Inc. →

BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.

M&A Activity · Americas

Biogen →

Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.

M&A Activity · Americas

Bristol Myers Squibb →

Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal

M&A Activity · Americas

Gilead Sciences →

Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio

Where this lands in our work

Weekly briefing

Track companies like Teva Pharmaceuticals — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record